Loading…

Surgical treatment of vena cava leiomyosarcomas: Series of cases in a referral center and literature review

Primary tumors of the inferior vena cava are rare tumors of mesenchymal origin. They arise from the smooth muscles of the vena cava wall. Due to its low prevalence, there are few definitive data on its treatment and prognosis. Its treatment is based on general oncological principles. A series of six...

Full description

Saved in:
Bibliographic Details
Published in:Cirugia española (English ed.) 2022-08
Main Authors: Pérez-de-Villar, José Manuel, Arjona-Sanchez, Alvaro, Rufián-Andujar, Blanca, Valenzuela-Molina, Francisca, Sánchez-Hidalgo, Juan Manuel, Rodriguez-Ortiz, Lidia, Casado-Adam, Angela, Viyuela-García, Cristina, Rufián-Peña, Sebastián, Caro-Cuenca, Teresa, Moreno-Vega, Alberto, Briceño-Delgado, Javier
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Primary tumors of the inferior vena cava are rare tumors of mesenchymal origin. They arise from the smooth muscles of the vena cava wall. Due to its low prevalence, there are few definitive data on its treatment and prognosis. Its treatment is based on general oncological principles. A series of six cases operated from 2010 to 2020 were analyzed. Different parameters related to the demographic characteristics, the tumor, the treatment received, and the results obtained in survival and morbidity were analyzed. In addition, a bibliographical review of the currently available evidence was carried out. Optimal surgical resection was accomplished in all patients with R0 in 4/6 and R1 in 2/6. The greatest morbidity occurred in a patient who died in the intraoperative period. Cavography was performed in one patient and cavoplasty in 5/6 using cryopreserved graft in 3/6 and prothesis in 2/6. The 50% were still alive at the end of the follow-up (with a mean follow-up of 10.7 months). The mean survival was 11.3±9.07 months. 3/6 patients presented hematogenous recurrences with a disease-free interval of 9±2 months. The diagnosis and treatment of inferior vena cava leiomyosarcoma is still a challenge. Due to its low prevalence, it will be difficult to establish a totally standardized treatment and its approach is recommended in specialized centers. On the other hand, a multicentric study should be made to collect the most cases as possible in order to advance in the understanding of the approach to this disease.
ISSN:2173-5077
DOI:10.1016/j.ciresp.2021.05.001